This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.

1. Gary M. Myles, Ph.D.
MYLES INTELLECTUAL PROPERTY LAW, PS
PO BOX 2049 • ISSAQUAH, WA 98027
Mobile 425.466.8262
gary@mylesip.com
www.linkedin.com/in/garymyles/
EDUCATION
University of Washington School of Law • Seattle, Washington, J.D., June 1999
Fred Hutchinson Cancer Research Center • Seattle, Washington, Post-doctoral, Dec. 1990-June 1996
University of North Carolina • Chapel Hill, North Carolina, Ph.D., Biochemistry and Biophysics, Dec. 1990
University of Michigan • Ann Arbor, Michigan; graduate course work, Chemical Engineering, 1981-1982
University of Illinois • Urbana-Champaign, Illinois, B.S., Biochemistry, May 1981
LEGAL EXPERIENCE
Myles Intellectual Property Law, PS • Issaquah, Washington
President & CEO, March 2016 to Present
Biotechnology and medical device related patent strategy and counseling, patent drafting and prosecution, and IP
licensing, negotiation, and dispute resolution for startup and mid-size biotechnology companies, universities and
non-profit research institutions, and large agricultural biotechnology companies. Manage complex biotechnology
patent portfolios; render freedom-to-operate, non-infringement, and invalidity opinions; and perform intellectual
property due diligence for transactions including M&A and venture financing.
Lowe Graham Jones • Seattle, Washington
Member, February 2014 to February 2016
Lead biotechnology patent prosecutor
Merchant & Gould • Seattle, Washington
Of Counsel, January 2012 to present
Lead biotechnology patent prosecutor in Seattle office
Keiretsu Forum Northwest • Seattle, Washington
Member, January 2013 to present
Intellectual property due diligence in support of angel investments in early- to mid-stage companies
Schwabe, Williamson & Wyatt • Seattle, Washington
Shareholder, February 2009 to December 2011
Lead biotechnology patent prosecutor in Seattle office
Darby & Darby PC • Seattle, Washington
Associate Attorney, November 2005 to February 2009
• Patent counseling, patent application drafting, patent prosecution and related licensing, intellectual property
portfolio evaluation and dispute resolution advice to life science clients
• Freedom-to-operate, non-infringement, and invalidity opinions and intellectual property due diligence reviews
for clients in the biotechnology, biomedical device, and mechanical device industries
• 2nd chair litigation on complex biotechnology patent dispute involving lentiviral vector technology
Speckman Law Group PLLC • Seattle, Washington
Patent Attorney, June 2002 to November 2005
• Patent counseling, patent application drafting, patent prosecution and related licensing, intellectual property
portfolio evaluation and dispute resolution advice to life science clients
• Freedom-to-operate, non-infringement, and invalidity opinions and intellectual property due diligence reviews
for clients in the biotechnology, biomedical device, and mechanical device industries

2. Gary M. Myles, Ph.D.
2
Corixa Corporation • Seattle, Washington
Patent Attorney, January 2001 to May 2002
Oversaw major portion of U.S. and foreign patent portfolio. Drafted and prosecuted patent applications in areas of
tumor antigen, infectious disease and autoimmune vaccines, therapeutics and diagnostics and direct outside counsel
in same. Researched and formulated patentability, freedom-to-operate and non-infringement opinions. Interfaced
with company scientists to identify new intellectual property and licensing opportunities. Worked with business
development group to facilitate patent in- and out-licensing. Reviewed company contracts for potential intellectual
property and other legal issues. Met with corporate partners to discuss and develop patent strategies consistent
with business agreements.
Seed Intellectual Property Law Group PLLC • Seattle, Washington
Chemical and Biotechnology Practice Group
Associate Attorney, August 1999 to December 2000
Law Clerk, April 1999 to July 1999
• Prepared and prosecuted U.S. and foreign biotechnology patent applications for domestic and foreign clients
• Researched and drafted patentability, freedom-to-operate and non-infringement opinions
• Consulted with clients to develop strategies for obtaining patent protection consistent with business plan
Townsend & Townsend & Crew LLP • Seattle, Washington
Chemical and Biotechnology Practice Group
Technical Advisor/Law Clerk, July 1996 to December 1998
• Drafted and prosecuted biotechnology patent applications
• Analyzed conception and reduction-to-practice in biotechnology patent interferences
• Completed patent and prior art search for and draft of non-infringement and freedom-to-operate opinions
BAR ADMISSIONS
Washington State Bar • Bar No. 29,684 • November 22, 1999 to present
United States Patent and Trademark Office • Registration No. 46,209 • 1999 to present
United States District Court for Western District of Washington • 2000 to present
LAW SCHOOL TEACHING EXPERIENCE
Seattle University School of Law • Seattle, Washington
Adjunct Professor of Law, March 2004 to present
• Teach course “Biotechnology and the Law” with emphasis on the nexus between law, technology, and business
• Coach new companies on developing business plans for and participate in SU business plan competition
University of Washington School of Law • Seattle, Washington
Adjunct Professor and Law, Technology & Arts Fellow, November 2002 to present
• Teach course “Advanced Patent Law” to JD and LLM students
• Mentor students in the preparation of research papers for LLM program
• Coach new companies on developing business plans for and participate in UW business plan competition
University of Illinois School of Law • Champaign-Urbana, Illinois
Guest Lecturer, October 2009 to present
• Teach classes on biotechnology patent law to JD students
• Mentor students on career options for the professional life scientist
BOARD OF DIRECTORS
HiveBio Community Lab • Seattle, Washington
Member of the Board of Directors, May 2013 to present
• Organizational leadership and advisement
• Formulation and oversight of policies and procedures
• Adoption and oversight of the annual budget
• Oversight of program planning and evaluation

3. Gary M. Myles, Ph.D.
3
• Personnel evaluation and staff development
• Review of organizational and programmatic initiatives
• Promotion of the organization
• Outreach and suggestions of funding sources for the organization
HONORS
Seattle IP Inn of Court
Seattle University School of Law and University of Washington Law School, 2010 to present
Washington Super Lawyers
Washington Law and Politics, 2010 and 2011
Law, Technology & Arts Fellow
University of Washington Law School
LEGAL SEMINARS AND PUBLICATIONS
Singh, A., Timm-Schreiber, M., Kowalchyk, K., and Myles, G.
“Myriad Decision May Invalidate Many Patents”
Today’s General Counsel, 37-39 (December/January 2014)
“Patenting Biotechnology Inventions after Myriad and Prometheus: The Supreme Court Reigns in the
Eligibility of Products and Laws of Nature”
HiveBio Community Laboratory, Seattle, WA • December 4, 2013
“Career Options for the Professional Life Scientist: Graduate School, Post-Doc, and Weighing the
Opportunity Costs of a Higher Education”
Renton Community College, Renton, WA • December 4, 2013
“Intellectual Property 101: Protecting Inventions through Patents”
HiveBio Community Laboratory, Seattle, WA • November 13, 2013
“35 U.S.C. § 101: Biotechnology Patent Eligibility”
University of Illinois School of Law, Champaign-Urbana, IL • October 29, 2013
“Biotechnology Utility and Patent Eligibility under 35 U.S.C. § 101”
University of Washington School of Law, Seattle, WA • October 3, 2013
“Protecting Inventions of Start-ups”
Icogenex Corporation, Seattle, WA • June 27, 2013
“FDA Approval of Follow-on Biologics: Update on Legislation and Process”
Merchant & Gould Chemical and Life Sciences Group, Seattle, WA • June 25, 2013
“Association for Molecular Pathology v. Myriad Genetics, Inc.: Isolated, Naturally Occurring DNAs are
Patent Ineligible Products of Nature”
The Edge, Merchant & Gould’s White Paper • June 2013
“Keeping the Devil out of the Details: An Ounce of Prevention is Worth a Pound of Cure”
Preparing for Financial, Tax, Corporate, and Intellectual Property Due Diligence
Merchant & Gould, Peterson Sullivan, and Summit Law Group Co-sponsored Biotechnology Seminar
• Novelty Hill – Januik Winery, Woodinville, WA • March 27, 2013
• The Pan Pacific Hotel, Seattle, WA • March 19, 2013
“Biotechnology Patents: Disclosure Requirements under 35 U.S.C. §§ 101 and 112, First Paragraph”
Seattle University School of Law, Seattle, WA • March 13, 2013
“Biotechnology Patent Eligibility under 35 U.S.C. §§ 101”
Seattle University School of Law, Seattle, WA • February 20, 2013

4. Gary M. Myles, Ph.D.
4
“Patent Protection for Products of Nature after Monsanto v. Syngenta”
University of Washington School of Law, Seattle, WA • January 2013
“Biotechnology Utility, Enablement, and Written Description”
University of Washington School of Law, Seattle, WA • October 2012
“Patenting Human DNA, Embryos and Organs: Recent Case Law Developments in the United States”
CASRIP High Technology Protection Summit
University of Washington School of Law, Seattle, WA • July 2012
“America Invents Act: Recent Changes to the Patent Law”
University of Washington School of Law, Seattle, WA • February 2012
“Biotechnology: Technology, Role of Patents, and Patent Eligibility under 35 U.S.C. § 101”
University of Washington School of Law, Seattle, WA • February 2012
Participant in Panel Discussion on America Invents Act; “Immediate Impacts on Patent Transactions”
Law Seminars International, Seattle, WA • January 2012
“Recent Changes to U.S. Patent Law and How They Impact Patent Protection and Valuation”
Licensing Executives Society, Seattle Chapter • November 2011
Symposium Participant; “Establishing and Managing Cross-Institutional Research Collaborations”
Presentation entitled “Recent Changes Impacting Patent Rights and IP Valuations in Inter-Institutional
Collaborations”
Annual Conference of Society of Research Administrators International, Montreal, Quebec • October 2011
“Biotechnology: Technology, Role of Patents, and Patent Eligibility under 35 U.S.C. § 101”
University of Illinois School of Law, Champaign, IL • October 2011
Co-chair of Program Committee for Symposium “Patenting in the Biotechnology Industry: 30 Years after
Diamond v. Chakrabarty”
University of Illinois, Champaign, IL • September 2010
Schwabe, Williamson & Wyatt Career Seminar; “Career Options for the Professional Life Scientist”
Fred Hutchinson Cancer Research Center, Seattle, WA • June 2010
University of Illinois, Champaign, IL • September 2009
Schwabe, Williamson & Wyatt IP Seminar; “Biotechnology Process Inventions: Patentable Subject Matter
after In Re Bilski”
Seattle, WA • March 18, 2009
Davison, E. M. and Myles, G.M.
“How Biotech Patentees can Navigate KSR”
Managing Intellectual Property, 79-82 (July/August 2008)
Darby & Darby IP Seminar; “Inequitable Conduct and the Duty of Disclosure: The Road to Hell is Paved
with Good Intentions”
Vancouver, BC • December 5, 2008
Darby & Darby IP Seminar; “Determining Obviousness after the Supreme Court Blast in KSR–-It’s Déjà
vu all over Again”
Seattle, WA • March 19, 2008
Darby & Darby IP Seminar; “The Coming Change in U.S. Patent Law: Patent Reform Act of 2007”
Vancouver, BC • December 3, 2007
Darby & Darby IP Seminar; “Strategic Options in View of Recent Patent Case Law”
Seattle, WA • March 21, 2007
Presentation entitled “Challenging the Obviousness Standard: KSR v. Teleflex

5. Gary M. Myles, Ph.D.
5
Darby & Darby IP Seminar; “Repelling the Invasion of the Patent Snatchers: Patent Strategies in View of
an Unpredictable Federal Circuit”
Portland, OR • October 25, 2006 Vancouver, BC • October 26, 2006
Palo Alto, CA • November 7, 2006 Seattle, WA • November 8, 2006
Presentation entitled “Disappearance of the Continuation-in-Part: Chiron v. Genentech and Other Federal Circuit
Decisions Alien to Traditional Patent Practice
Darby & Darby IP Seminar; “A Coming Sea Change in Patent Law: Are You Ready to Navigate the
Perfect Storm?”
Seattle, WA • March 22, 2006
Presentation entitled “Preparing for Intellectual Property Due Diligence in Connection with Venture Financing”
Lorman Educational Services
October 21, 2003
Seminar entitled “Management of Intellectual Property Documents”
PRO BONO
University of Washington School of Law • Seattle, WA
Entrepreneurial Law Clinic; 2005 to present
Oversee student representation of clinic clients in matters relating to patents, trademarks, copyrights, and trade
secrets
Washington Biotechnology and Biomedical Association • Seattle, WA
Invest Northwest 2007
Co-chair of Selection and Recruitment Committee for 2007 conference at Bell Harbor in Seattle, WA
PROFESSIONAL AND COMMUNITY MEMBERSHIPS
Washington State Bar Association
American Bar Association
Washington State Patent Law Association
American Intellectual Property Law Association
Licensing Executives Society
Association of University Technology Managers
Washington Biotechnology and Biomedical Association
SCIENTIFIC EXPERIENCE
Fred Hutchinson Cancer Research Center • Seattle, Washington
Basic Sciences Division - Department of Cell Biology
Senior Research Fellow, 1993-1996
Training Grant #T32 CA09437 - University of Washington, Department of Pathology
Postdoctoral Research Associate, 1990-1993
• Researched the molecular mechanisms of signal transduction initiated by the c-fms protooncogene product
expressed in a murine myeloid cell line
• Performed two-hybrid screening method to identify and clone cellular substrates of the c-Fms cytoplasmic
domain
• Identified sites of in vivo tyrosine autophosphorylation and assessed role of c-Fms phosphorylation in cellular
differentiation and proliferation through construction and expression of site-directed c-Fms point mutants
• Performed studies on the molecular mechanism of c-Fms M-CSF-dependent endocytosis and potential role in
cellular differentiation and proliferation
University of North Carolina • Chapel Hill, North Carolina
Research Assistant, School of Medicine - Department of Biochemistry and Biophysics, 1984-1990
Ph.D. Dissertation: “Structure-Function Studies on UvrA: An Escherichia coli DNA Repair Protein”
• Performed experiments on the molecular mechanism of the E. coli UvrABC excinuclease DNA nucleotide
excision repair complex

6. Gary M. Myles, Ph.D.
6
• Created site-directed point mutants in conserved DNA-binding and ATPase active site residues of UvrA and
assessed the effect of these mutations on DNA repair in vitro and in vivo
• Prepared plasmid constructs expressing UvrA functional domains, purified domain polypeptides, assessed DNA
binding and ATPase activities in vitro and characterized the role of each functional domain in E. coli DNA repair
Abbott Laboratories • Abbott Park, Illinois
Research Technician, Hepatitis Business Unit, Research and Development, 1983-1984
• Assisted in the development of an automated instrument for use in detecting blood-borne pathogens, e.g.,
Hepatitis and HIV
• Troubleshot false positives identified in biological assays
• Collaborated with project engineers to improve instrument performance prior to field studies
University of Michigan • Ann Arbor, Michigan
Teaching Assistant, Department of Biology, Spring of 1982
• Taught a laboratory course in basic microbiological methods
Argonne National Laboratory • Argonne, Illinois
Student Aide, Department of Biology in Medicine, Summers of 1979 and 1980
• Provided technical assistance on environmental impact studies related to an experimental fluidized bed coal
combustor
SCIENTIFIC PUBLICATIONS AND ABSTRACTS
Bourette R.P., Arnaud S., Myles G.M., Blanchet J.P., Rohrschneider L.R., and Mouchiroud G. (1998) Mona,
a Novel Hematopoietic-Specific Adapter Interacting with the Macrophage-Colony-Stimulating Factor Receptor is
Implicated in Monocyte/Macrophage Development. EMBO Journal 17(24):7273-81.
Bourette, R.P., Myles, G.M., Choi, J.L., and Rohrschneider, L.R. (1997) Sequential Activation of
Phosphatidylinositol 3-Kinase and Phospholipase C-Gamma2 by the M-CSF Receptor is Necessary for
Differentiation Signaling. EMBO Journal 16(19):5880-93.
Rohrschneider, L.R., Bourette, R.P., Lioubin, M.N., Algate, P.A., Myles, G.M., and Carlberg, K. (1997)
Growth and Differentiation Signals Regulated by the M-CSF Receptor. Molecular Reproduction and
Development 46(1):96-103.
Bourette, R.P., Myles, G.M., Carlberg, K., Chen, A.R., and Rohrschneider, L.R. (1995) Uncoupling of the
Proliferation and Differentiation Signals Mediated by the Murine Macrophage Colony-Stimulating Factor
Expressed in Myeloid FDC-P1 Cells. Cell Growth and Differentiation 6(6):631-45.
Lioubin, M.N., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) Shc, Grb2, Sos1, and a 150-
kilodalton Tyrosine-Phosphorylated Protein form Complexes with Fms in Hematopoietic Cells. Molecular and
Cellular Biology 14(9):5682-91.
Myles, G.M., Brandt, C.S., Carlberg, K., and Rohrschneider, L.R. (1994) Tyrosine 569 in the c-Fms
Juxtamembrane Domain is Essential for Kinase Activity and Macrophage Colony-Stimulating Factor-Dependent
Internalization. Molecular and Cellular Biology 14(7):4843-54.
Lioubin, M.N., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) SHC, Grb2, SOS1, and a Novel
150 kDa Tyrosine Phosphorylated Protein form Complexes with Fms in Hematopoietic Cells. Tenth Annual
Meeting on Oncogenes, Foundation for Advanced Cancer Studies, Inc.
Carlberg, K., Lioubin, M.N., Myles, G.M., and Rohrschneider, L.R. (1994) Tyrosine 807 in Murine c-Fms
has a Role in Regulating both Receptor Tyrosine Phosphorylation and Substrate Interactions. Tenth Annual
Meeting on Oncogenes, Foundation for Advanced Cancer Studies, Inc.
Bourette, R.P., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) Mutation of Tyrosine 807
Abrogates the Differentiation but not the Proliferation Signal of the Murine M-CSF Receptor Expressed in
Myeloid FDC-P1 cells. Tenth Annual Meeting on Oncogenes, Foundation for Advanced Cancer Studies, Inc.

7. Gary M. Myles, Ph.D.
7
Wang, Z.E., Myles, G.M., Brandt, C.S., Lioubin, M.N., and Rohrschneider, L.R. (1993) Identification of the
Ligand-Binding Regions in the Macrophage Colony-Stimulating Factor Receptor Extracellular Domain.
Molecular and Cellular Biology 13(9):5348-59.
Myles, G.M., Brandt, C.S., and Rohrschneider, L.R. (1992) Identification of a Domain in the c-Fms
Cytoplasmic Domain Essential for M-CSF-Dependent Internalization. Eighth Annual Meeting on Oncogenes.
Foundation for Advanced Cancer Studies, Inc.
Rohrschneider, L.R., Wang, Z., Myles, G.M., and Brandt, C.S. (1992) Identification of the Ligand Binding
Region on the Murine M-CSF Receptor Extracellular Domain, and a Cytoplasmic Sequence Necessary for
Internalization. The Biochemical Society 38th Harden Conference.
Myles, G.M. and Sancar, A. (1991) Isolation and Characterization of Functional Domains of UvrA.
Biochemistry 30(16):3834-38.
Myles, G.M., Hearst, J.E., and Sancar, A. (1991) Site-Specific Mutagenesis of Conserved Residues within
Walker A and B Sequences of Escherichia coli UvrA Protein. Biochemistry 30(16):3824-24.
Myles, G.M. and Sancar, A. (1989) DNA Repair. Chemical Research in Toxicology 2(4):197-226.
Navaratnum, S., Myles, G.M., Strange, R.W., and Sancar, A. (1989) Evidence from Extended X-ray
Absorption Fine Structure and Site-Specific Mutagenesis for Zinc Fingers in UvrA Protein of Escherichia coli.
Journal of Biological Chemistry 264:16067-71.
Myles, G.M., Van Houten, B., and Sancar, A. (1987) Utilization of DNA Photolyase, Pyrimidine Dimer
Endonucleases, and Alkali Hydrolysis in the Analysis of Aberrant ABC Excinuclease Incisions Adjacent to UV-
Induced DNA Photoproducts. Nucleic Acids Research 15(3):1227-43.